FDA Launches ISTAND Procedure for Validating New Drug Development Tools, Including Integral Molecular
Background of the Formal Institutionalization of the FDA ISTAND Program
In July 2025, the FDA will transition its ISTAND program, which began as a pilot project in November 2020, into a permanent program. This decision is driven by the increasing demand for regulatory validation of cutting-edge platforms, such as artificial intelligence (AI) and organ-on-a-chip technologies, which go beyond the scope of traditional biomarkers and clinical outcome assessments (COAs). By proactively providing guidelines, the regulatory agency is significantly reducing the uncertainties faced by next-generation biotech companies during the clinical entry phase. Ultimately, it is expected to accelerate technological collaboration between platform companies with new technologies and multinational pharmaceutical companies seeking to adopt them.
Systematic Validation Through a Three-Step Submission Process
The ISTAND evaluation process consists of a rigorous three-step process: a Letter of Intent (LOI), a Qualification Plan (QP), and a Full Qualification Package (FQP). Applicants must first submit a Letter of Intent (LOI) via email, outlining the context of use (COU) and preliminary data for the new technology. Subsequently, they submit a detailed qualification plan through the NextGen Collaboration Portal and, upon approval, submit the final package. This step-by-step feedback mechanism serves as a critical safeguard, preventing companies from wasting significant validation budgets and time.
Current Status of Innovative Technology Submissions by Leading Companies
Integral Molecular's antibody off-target screening platform, the Membrane Proteome Array (MPA), has been the first to receive approval for its Letter of Intent. Emulate's Liver-Chip and Deliberate AI's neuroscience assessment tool have also subsequently joined the program. Once these leading platform technologies obtain qualification as validated drug development tools, other drug developers will be able to immediately utilize them in regulatory submissions without requiring separate validation. This is a positive sign that directly leads to an increase in the market value of platform-owning companies and expands technology licensing opportunities. The industry is closely watching how proprietary technologies will be standardized and incorporated into regulatory frameworks.
Maximizing Clinical Efficiency and Reducing Costs in the Bioecosystem
Ultimately, the clarification of this submission process is expected to revolutionize drug research and development (R&D) productivity and transform the paradigm of clinical trials. In particular, AI-based patient screening and organ-on-a-chip technologies are powerful tools that can improve the accuracy of adverse event prediction in preclinical and early clinical stages, thereby reducing clinical failure rates. By using pre-validated standard tools, both large pharmaceutical companies targeting the entire indication market and small-to-medium-sized biotech ventures can acquire time and cost savings and maximize development efficiency. Creating a rapid and safe drug development ecosystem will contribute to addressing unmet medical needs for patients in the long term.
The FDA's clarification of the ISTAND program submission process is a decision that lays the groundwork for the institutional framework of the organ-on-a-chip and AI-based digital healthcare markets, which are projected to grow by more than 24% annually and reach tens of billions of dollars in the early 2030s. It provides a clear regulatory pathway for platform technologies that can replace or supplement traditional preclinical animal studies, such as Integral Molecular's Membrane Proteome Array (MPA) and Emulate's Liver-Chip, to be officially recognized. In the short term, it is expected to contribute to the increase in corporate value and the improvement of technology export transaction terms for individual biotech ventures that possess these innovative platforms. In the medium to long term, it will induce ecosystem-wide innovation in drug development by enabling global drug developers to quickly incorporate validated tools into clinical phase 1/2/3 designs and new drug applications (NDAs/BLAs) without separate validation, leading to cost savings and shorter development times. This will serve as a catalyst that significantly reduces regulatory risk and further increases the likelihood of success for new pipelines for investors and researchers.